These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23341049)

  • 1. Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.
    Latimer NR
    Med Decis Making; 2013 Aug; 33(6):743-54. PubMed ID: 23341049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions.
    Grutters JP; Seferina SC; Tjan-Heijnen VC; van Kampen RJ; Goettsch WG; Joore MA
    Value Health; 2011; 14(5):777-84. PubMed ID: 21839418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.
    Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
    Med Decis Making; 2022 Oct; 42(7):945-955. PubMed ID: 35769004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
    Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
    Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
    Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
    Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(5):1-70. PubMed ID: 23074496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests.
    Smith AF; Messenger M; Hall P; Hulme C
    Pharmacoeconomics; 2018 Jul; 36(7):823-835. PubMed ID: 29502176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review.
    Tappenden P; Campbell F; Rawdin A; Wong R; Kalita N
    Health Technol Assess; 2012; 16(20):1-72. PubMed ID: 22490205
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.